 Home > Medical News > Latest Medical News > GSK's first-quarter results failed to meet expectations, and more anti-cancer drug investment will be reduced in the future

GSK's first-quarter results failed to meet expectations, and more anti-cancer drug investment will be reduced in the future

 Last Update: 2021-05-22
 Source: Internet
 Author: User

Tags

cancer cell culture

companies failed innovate

u937 cell line

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compileriver

A few days ago, GSK released its first quarter financial report.

GSK experienced several major oncology setbacks in the first quarter.

In the first quarter report, GSK revealed that due to the priority of its product portfolio, the company will abandon the phase I development plan of DMD's hematopoietic prostaglandin D2 synthase inhibitor GSK3439171 and the oncology drug candidate GSK3537142 in cooperation with Immunocore.

Immunocore company signed an agreement with GSK as early as 2013 to sell its ImmTAC molecule, which is designed to change the direction of the immune system to recognize and kill cancer cells.

Hal Barron was once seen by GSK as a hope to revive oncology, but he suffered a series of setbacks, including mid-term failure, which led the company to abandon its induction of T cell costimulation (ICOS) agonist feladilimab earlier this month.

In addition, the future CEO of GSK Emma Walmsley will focus on the spin-off plan for the consumer healthcare business next year.

Reference source: The pressure builds for Emma Walmsley as GlaxoSmithKline misses Q1 projection, drops more cancer drugs

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.